Physician profile
Alaina Lopp
NPI 1629700182
$1,055.74
in general payments reported to CMS, 2019-2025
30 companies · $707 in 2025
The $707 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $349 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.74 |
| Education | $197.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $112.71 | 2025 | Xtandi |
| Gilead Sciences, INC. | $111.78 | 2024-2025 | Trodelvy |
| Medical Device Business Services, INC. | $98.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $69.16 | 2024-2025 | |
| Kite Pharma, INC. | $57.92 | 2024-2025 | Yescarta |
| Merck Sharp & Dohme LLC | $55.57 | 2025 | Keytruda, Welireg |
| E.R. Squibb & Sons, L.L.C. | $35.23 | 2024-2025 | Opdivo, Krazati |
| Array Biopharma INC | $34.67 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Exelixis INC. | $33.15 | 2025 | Cabometyx |
| Abbvie INC. | $30.12 | 2025 | |
| Deciphera Pharmaceuticals INC. | $26.30 | 2025 | Qinlock |
| Genzyme Corporation | $25.87 | 2024 | |
| Alexion Pharmaceuticals, INC. | $25.75 | 2025 | Ultomiris |
| Lilly USA, LLC | $25.28 | 2025 | |
| Eisai INC. | $24.46 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $23.54 | 2024 | Alecensa, Tecentriq |
| Kyowa Kirin, INC. | $23.39 | 2025 | |
| Genmab U.S., INC. | $22.65 | 2025 | Epkinly |
| Aveo Pharmaceuticals, INC. | $22.57 | 2024 | |
| Medtronic, INC. | $21.79 | 2024 | Signia |
| Rigel Pharmaceuticals, INC. | $21.54 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Bayer Healthcare Pharmaceuticals INC. | $20.70 | 2025 | |
| Daiichi Sankyo INC. | $19.59 | 2025 | Injectafer |
| Incyte Corporation | $19.39 | 2024 | Jakafi |
| Recordati_rare_diseases_inc. | $18.90 | 2025 | Enjaymo |
| Sobi, INC | $17.44 | 2024 | |
| Beigene USA, INC. | $17.22 | 2025 | Brukinsa |
| Beone Medicines USA, INC. | $15.31 | 2025 | Brukinsa |
| Puma Biotechnology, INC. | $14.62 | 2024 | |
| Iovance Biotherapeutics, INC. | $11.12 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alaina Lopp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.